Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Dec 06, 2022 3:59pm
107 Views
Post# 35154362

RE:RE:RE:12/13 Goblet PC patients had Stage IV metastatic (M1) cancer

RE:RE:RE:12/13 Goblet PC patients had Stage IV metastatic (M1) cancerThe patient that demonstrated a CR at week 40 (end-of-trial) was patient #C1-002 a 54 year old male who had his cancer spread to his pertonieum.

The others had experienced partial responses (PR) to their cancer.

Best responses for the 13 evaluable patients at cut-off date: CR=1, PR=8, SD=2 and PD=2. Of the 9 patients with CR or PR, 7 responses were confirmed by a subsequent scan. ORR and clinical benefit rate (CBR) are 69% and 85%, respectively.  Largest tumor diameter decreased from 30 mm at baseline to too small to measure at Week 24.
<< Previous
Bullboard Posts
Next >>